




*p<0.001 versus control; ††p<0.01 and †††p<0.001 versus atorvastatin metabolite (within O3FA-treatment group); §§p<0.01 and §§§p<0.001 versus cognate EPA-treated samples; ¶¶p<0.01 and ¶¶¶p<0.001 versus cognate DHA-treated samples (Student-Newman-Keuls multiple comparisons post-hoc test; overall ANOVA: p<0.0001, F=19.485).

FIG. 1




*$p<0.001$ versus control; †$p<0.01$ versus EPA + atorvastatin metabolite (Student-Newman-Keuls multiple comparisons post-hoc test; overall ANOVA: $p<0.0001$, $F=176.75$).

FIG. 2




*$p<0.001$ versus control; †$p<0.01$ and ††$p<0.001$ versus DHA + atorvastatin metabolite; §$p<0.05$ and §§$p<0.001$ versus DHA + atorvastatin; ¶$p<0.001$ versus DHA + simvastatin (Student-Newman-Keuls multiple comparisons post-hoc test; overall ANOVA: $p<0.0001$, $F=55.947$).

FIG. 3




*$p<0.001$ versus control; †$p<0.01$ versus EPA/DHA + atorvastatin metabolite; §$p<0.05$ and §§$p<0.01$ versus EPA/DHA + atorvastatin (Student-Newman-Keuls multiple comparisons post-hoc test; overall ANOVA: $p<0.0001$, $F=18.526$).

FIG. 4




*p<0.001 versus control; $^{\dagger\dagger}p$<0.01 and $^{\dagger\dagger\dagger}p$<0.001 versus cognate EPA treatment (within statin treatment group); $^{\S\S}p$<0.01 and $^{\S\S\S}p$<0.001 versus cognate DHA treatment (within statin treatment group) (Student-Newman-Keuls multiple comparisons post-hoc test; overall ANOVA: p<0.0001, F=19.485).

FIG. 5




*p<0.001 versus control (Student-Newman-Keuls multiple comparisons post-hoc test; overall ANOVA: p<0.0001, F=291.05).

FIG. 6




*$p<0.001$ versus control (Student-Newman-Keuls multiple comparisons post-hoc test; overall ANOVA: $p<0.0001$, $F=291.05$).

FIG. 7



*p<0.001 versus control; †p<0.001 versus either simvastatin + EPA or simvastatin + EPA/DHA (Student-Newman-Keuls multiple comparisons post-hoc test; overall ANOVA: p<0.0001, F=92.185).

FIG. 8



*p<0.001 versus control; †p<0.001 versus either rosuvastatin +EPA or rosuvastatin + EPA/DHA (Student-Newman-Keuls multiple comparisons post-hoc test; overall ANOVA: p<0.0001, F=157.90).

FIG. 9